You Should Watch These: The Gap, Inc., Helen of Troy Limited (NASDAQ:HELE), Spark Therapeutics (NASDAQ:ONCE), Pacific Biosciences of California (NASDAQ:PACB)

RadNet, Inc. (NASDAQ:RDNT) shares moved down -3.88% in last trading session and ended the day at $5.70. RDNT Gross Margin is 20.00% and its has a return on assets of 1.00%. RadNet, Inc. (NASDAQ:RDNT) quarterly performance is -13.24%.

On 30 September, RadNet, Inc. (NASDAQ:RDNT) and Barnabas Health completed the previously announced expansion of their existing New Jersey Imaging Networks (“NJIN”) joint venture which includes NJIN’s acquisition of all of RadNet’s 10 wholly owned New Jersey imaging centers and Barnabas Health’s wholly owned outpatient imaging center in West Orange, New Jersey.

The Gap, Inc. (NYSE:GPS) ended the last trading day at $28.95. Company weekly volatility is calculated as 3.47% and price to cash ratio as 11.29. The Gap, Inc. (NYSE:GPS) showed a weekly performance of 4.40%.

Gap Inc.’s (NYSE: GPS) comparable sales for September 2015 were down 1 percent versus flat last year. Comparable sales by global brand for September 2015 were as follows: Gap Global: flat versus negative 3 percent last year; Banana Republic Global: negative 10 percent versus positive 2 percent last year; Old Navy Global: positive 4 percent versus positive 1 percent last year.

On 08 October, Helen of Troy Limited (NASDAQ:HELE) shares moved down -0.39% and was closed at $94.76. HELE EPS growth in last 5 year was 14.30%. Helen of Troy Limited (NASDAQ:HELE) year to date (YTD) performance is 45.65%.

Helen of Troy Limited (NASDAQ:HELE) posted quarterly net income of $24.5 million, or $0.84 per share, compared to $18.8 million, or $0.65 per share, in the year-earlier quarter. Excluding items, adjusted earnings climbed to $1.12 per share from $0.99 per share. Its net sales revenue surged 15.4 percent year-over-year to $369.1 million from $319.9 million. However, analysts were expecting a profit of $0.93 per share on revenue of $337.67 million.

Spark Therapeutics, Inc. (NASDAQ:ONCE) shares advanced 5.87% in last trading session and ended the day at $47.44. ONCE has a return on assets of -24.90%. Spark Therapeutics, Inc. (NASDAQ:ONCE) quarterly performance is -21.97%.

Spark Therapeutics (NASAQ:ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs).

Pacific Biosciences of California, Inc. (NASDAQ:PACB) caters to the Healthcare space. It has a net profit margin of -75.30% and weekly performance is 37.80%. On the last day of trading company shares ended up at $7.51. Pacific Biosciences of California, Inc. (NASDAQ:PACB) distance from 50-day simple moving average (SMA50) is 54.60%.

Pacific Biosciences of California, Inc., (NASDAQ:PACB) announced it has launched a new nucleic acid sequencing platform. The Sequel™ System provides higher throughput, more scalability, a reduced footprint and lower sequencing project costs compared to the PacBio® RS II System, while maintaining the existing benefits of the company’s SMRT Technology. Pacific Biosciences will showcase the new product at the American Society of Human Genetics annual meeting taking place in Baltimore, Maryland beginning October 6, 2015.